{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:44:58Z","timestamp":1774395898620,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T00:00:00Z","timestamp":1422403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00228-015-1807-1","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T06:38:18Z","timestamp":1422340698000},"page":"389-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Treatment of clozapine-associated weight gain: a systematic review"],"prefix":"10.1007","volume":"71","author":[{"given":"Z.","family":"Whitney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. H.","family":"Fredrikson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,28]]},"reference":[{"issue":"5","key":"1807_CR1","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2(5):e141","journal-title":"PLoS Med"},{"key":"1807_CR2","doi-asserted-by":"crossref","unstructured":"Koster LS, Carbon M, Correll CU (2014) Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs 19(4):1--21","DOI":"10.1517\/14728214.2014.958148"},{"issue":"11","key":"1807_CR3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","volume":"50","author":"RR Conley","year":"2001","unstructured":"Conley RR, Kelly DL (2001) Management of treatment resistance in schizophrenia. Biol Psychiatry 50(11):898\u2013911","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1807_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12888-014-0253-4","volume":"14","author":"D Sinclair","year":"2014","unstructured":"Sinclair D, Adams CE (2014) Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatr 14(1):253","journal-title":"BMC Psychiatr"},{"issue":"3","key":"1807_CR5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","volume":"6","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY (2012) Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6(3):134\u2013144","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"6","key":"1807_CR6","first-page":"433","volume":"34","author":"WG Honer","year":"2009","unstructured":"Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM (2009) A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci 34(6):433\u2013442","journal-title":"J Psychiatry Neurosci"},{"issue":"9618","key":"1807_CR7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085\u20131097","journal-title":"Lancet"},{"key":"1807_CR8","first-page":"135","volume":"7","author":"ME McIlwain","year":"2011","unstructured":"McIlwain ME, Harrison J, Wheeler AJ, Russell BR (2011) Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 7:135\u2013149","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"1807_CR9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1017\/S146114571100201X","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley C, Taylor D, Dickens G, Picchioni M (2012) A systematic review of the evidence of clozapine\u2019s anti-aggressive effects. Int J Neuropsychopharmacol 15(9):1351\u20131371","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6 Suppl 1","key":"1807_CR10","doi-asserted-by":"crossref","first-page":"59S","DOI":"10.1177\/07067437070526S106","volume":"52","author":"DC Mamo","year":"2007","unstructured":"Mamo DC (2007) Managing suicidality in schizophrenia. Can J Psychiatry 52(6 Suppl 1):59S\u201370S","journal-title":"Can J Psychiatry"},{"issue":"6","key":"1807_CR11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","volume":"40","author":"WW Shen","year":"1999","unstructured":"Shen WW (1999) A history of antipsychotic drug development. Compr Psychiatry 40(6):407\u2013414","journal-title":"Compr Psychiatry"},{"issue":"4","key":"1807_CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D","volume":"24","author":"CR Ashby Jr","year":"1996","unstructured":"Ashby CR Jr, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24(4):349\u2013394","journal-title":"Synapse"},{"key":"1807_CR13","doi-asserted-by":"crossref","first-page":"656370","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N (2014) Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014:656370","journal-title":"Biomed Res Int"},{"issue":"2","key":"1807_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","volume":"135","author":"JY Leung","year":"2012","unstructured":"Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC (2012) Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135(2):113\u2013122","journal-title":"Pharmacol Ther"},{"issue":"1\u20133","key":"1807_CR15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2012.06.020","volume":"140","author":"R Roge","year":"2012","unstructured":"Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J (2012) Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140(1\u20133):204\u2013213","journal-title":"Schizophr Res"},{"issue":"4","key":"1807_CR16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/1516-4446-2014-1402","volume":"36","author":"T Baptista","year":"2014","unstructured":"Baptista T (2014) A fatal case of ischemic colitis during clozapine administration. Rev Bras Psiquiatr 36(4):358","journal-title":"Rev Bras Psiquiatr"},{"issue":"Suppl 1","key":"1807_CR17","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1\u201393","journal-title":"CNS Drugs"},{"issue":"1","key":"1807_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80(1):19\u201332","journal-title":"Schizophr Res"},{"issue":"6","key":"1807_CR19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","volume":"34","author":"HN Boyda","year":"2010","unstructured":"Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, Barr AM (2010) A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 34(6):945\u2013954","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"1807_CR20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","volume":"31","author":"HN Boyda","year":"2010","unstructured":"Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31(10):484\u2013497","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1807_CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","volume":"125","author":"GP Reynolds","year":"2010","unstructured":"Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms. Pharmacol Ther 125(1):169\u2013179","journal-title":"Pharmacol Ther"},{"issue":"12","key":"1807_CR22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","volume":"25","author":"JL Roerig","year":"2011","unstructured":"Roerig JL, Steffen KJ, Mitchell JE (2011) Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 25(12):1035\u20131059","journal-title":"CNS Drugs"},{"issue":"1","key":"1807_CR23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1176\/ajp.149.1.68","volume":"149","author":"R Leadbetter","year":"1992","unstructured":"Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149(1):68\u201372","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1807_CR24","first-page":"33","volume":"22","author":"DC Henderson","year":"2010","unstructured":"Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC (2010) Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry 22(1):33\u201342","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"1807_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","volume":"59","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59(1):19\u201327","journal-title":"Schizophr Res"},{"issue":"2","key":"1807_CR26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3810\/pgm.2008.07.1786","volume":"120","author":"L Citrome","year":"2008","unstructured":"Citrome L, Vreeland B (2008) Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 120(2):18\u201333","journal-title":"Postgrad Med"},{"issue":"8","key":"1807_CR27","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","volume":"61","author":"A Tschoner","year":"2007","unstructured":"Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61(8):1356\u20131370","journal-title":"Int J Clin Pract"},{"key":"1807_CR28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1192\/bjp.171.6.502","volume":"171","author":"S Brown","year":"1997","unstructured":"Brown S (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171:502\u2013508","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1807_CR29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","volume":"26","author":"A DeLeon","year":"2004","unstructured":"DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26(5):649\u2013666","journal-title":"Clin Ther"},{"issue":"2","key":"1807_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","volume":"113","author":"DC Henderson","year":"2006","unstructured":"Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE, Goff DC (2006) An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113(2):142\u2013147","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"1807_CR31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","volume":"13","author":"WW Fleischhacker","year":"2010","unstructured":"Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115\u20131125","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9657","key":"1807_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31\u201341","journal-title":"Lancet"},{"issue":"3","key":"1807_CR33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hup.1012","volume":"24","author":"DC Henderson","year":"2009","unstructured":"Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC (2009) Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 24(3):225\u2013232","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"1807_CR34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1385\/ENDO:13:2:193","volume":"13","author":"DH Ryan","year":"2000","unstructured":"Ryan DH (2000) Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine 13(2):193\u2013199","journal-title":"Endocrine"},{"issue":"2","key":"1807_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0447.2006.00855.x","volume":"115","author":"DC Henderson","year":"2007","unstructured":"Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC (2007) A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115(2):101\u2013105","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"1807_CR36","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.286.8.930","volume":"286","author":"HM Blanck","year":"2001","unstructured":"Blanck HM, Khan LK, Serdula MK (2001) Use of nonprescription weight loss products: results from a multistate survey. JAMA 286(8):930\u2013935","journal-title":"JAMA"},{"issue":"4","key":"1807_CR37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4088\/JCP.v63n0412","volume":"63","author":"MC Borovicka","year":"2002","unstructured":"Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE (2002) Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 63(4):345\u2013348","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1807_CR38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.chc.2012.07.005","volume":"21","author":"B Vaughan","year":"2012","unstructured":"Vaughan B, Kratochvil CJ (2012) Pharmacotherapy of pediatric attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 21(4):941\u2013955","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"Suppl 12","key":"1807_CR39","first-page":"50","volume":"63","author":"JF Wernicke","year":"2002","unstructured":"Wernicke JF, Kratochvil CJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63(Suppl 12):50\u201355","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1807_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3371\/CSRP.5.1.3","volume":"5","author":"MP Ball","year":"2011","unstructured":"Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW (2011) Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5(1):17\u201325","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"3","key":"1807_CR41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","volume":"95","author":"A Verrotti","year":"2011","unstructured":"Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S (2011) Topiramate-induced weight loss: a review. Epilepsy Res 95(3):189\u2013199","journal-title":"Epilepsy Res"},{"issue":"4","key":"1807_CR42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/14740331003739196","volume":"9","author":"JJ Luykx","year":"2010","unstructured":"Luykx JJ, Carpay JA (2010) Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf 9(4):623\u2013631","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1807_CR43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0269881108089816","volume":"23","author":"H Afshar","year":"2009","unstructured":"Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, Talaei M (2009) Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 23(2):157\u2013162","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1807_CR44","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JCP.0b013e3181fab67d","volume":"30","author":"MK Hahn","year":"2010","unstructured":"Hahn MK, Remington G, Bois D, Cohn T (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30(6):706\u2013710","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1807_CR45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/hrp.11.5.230.244","volume":"11","author":"C Salzman","year":"2003","unstructured":"Salzman C (2003) New uses for lithium and anticonvulsants. Harv Rev Psychiatr 11(5):230\u2013244","journal-title":"Harv Rev Psychiatr"},{"issue":"1","key":"1807_CR46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01204.x","volume":"118","author":"C Torrent","year":"2008","unstructured":"Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M, Rosa AR, Scott J, Vieta E (2008) Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 118(1):4\u201318","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1807_CR47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.phrs.2010.04.002","volume":"62","author":"D Repantis","year":"2010","unstructured":"Repantis D, Schlattmann P, Laisney O, Heuser I (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62(3):187\u2013206","journal-title":"Pharmacol Res"},{"issue":"13","key":"1807_CR48","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2165\/00003495-200868130-00003","volume":"68","author":"R Kumar","year":"2008","unstructured":"Kumar R (2008) Approved and investigational uses of modafinil : an evidence-based review. Drugs 68(13):1803\u20131839","journal-title":"Drugs"},{"issue":"1\u20133","key":"1807_CR49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2011.04.009","volume":"130","author":"DC Henderson","year":"2011","unstructured":"Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, Fan X, Cather C, Goff DC (2011) Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res 130(1\u20133):53\u201356","journal-title":"Schizophr Res"},{"issue":"15","key":"1807_CR50","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1517\/14656566.6.15.2727","volume":"6","author":"B Dell\u2019Osso","year":"2005","unstructured":"Dell\u2019Osso B, Allen A, Hollander E (2005) Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 6(15):2727\u20132740","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1807_CR51","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","volume":"65","author":"ML Lu","year":"2004","unstructured":"Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65(6):766\u2013771","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1807_CR52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-2007-979221","volume":"32","author":"A Szegedi","year":"1999","unstructured":"Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32(4):148\u2013153","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"1807_CR53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3132\/dvdr.2008.027","volume":"5","author":"JH Scarpello","year":"2008","unstructured":"Scarpello JH, Howlett HC (2008) Metformin therapy and clinical uses. Diab Vasc Dis Res 5(3):157\u2013167","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"1807_CR54","first-page":"658","volume":"19","author":"H Nasri","year":"2014","unstructured":"Nasri H, Rafieian-Kopaei M (2014) Metformin: current knowledge. J Res Med Sci 19(7):658\u2013664","journal-title":"J Res Med Sci"},{"issue":"1","key":"1807_CR55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","volume":"113","author":"E Carrizo","year":"2009","unstructured":"Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, Valbuena D, Fernandez I, de Baptista EA, Baptista T (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113(1):19\u201326","journal-title":"Schizophr Res"},{"issue":"5","key":"1807_CR56","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.4088\/JCP.12m08186","volume":"74","author":"CH Chen","year":"2013","unstructured":"Chen CH, Huang MC, Kao CF, Lin SK, Kuo PH, Chiu CC, Lu ML (2013) Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 74(5):e424\u2013e430","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1807_CR57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281(3):235\u2013242","journal-title":"JAMA"},{"issue":"5","key":"1807_CR58","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.v69n0503","volume":"69","author":"G Joffe","year":"2008","unstructured":"Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, Eronen M, Rasanen P (2008) Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):706\u2013711","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1807_CR59","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.09m05283yel","volume":"72","author":"E Tchoukhine","year":"2011","unstructured":"Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, Terevnikov V, Stenberg JH, Eronen M, Joffe G (2011) Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 72(3):326\u2013330","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1807_CR60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1192\/bjp.bp.107.042853","volume":"193","author":"M Alvarez-Jimenez","year":"2008","unstructured":"Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193(2):101\u2013107","journal-title":"Br J Psychiatry"},{"issue":"9","key":"1807_CR61","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/j.1440-1614.2006.01888.x","volume":"40","author":"JK Sharpe","year":"2006","unstructured":"Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP (2006) Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 40(9):810\u2013814","journal-title":"Aust N Z J Psychiatry"},{"key":"1807_CR62","unstructured":"FAO\/WHO\/UNU (1985) Energy and protein requirements: report of a joint FAO\/WHO\/UNU expert consultation committee. World Health Organization, Geneva, (No. 724)"},{"issue":"4","key":"1807_CR63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ps.2007.58.4.544","volume":"58","author":"MK Wu","year":"2007","unstructured":"Wu MK, Wang CK, Bai YM, Huang CY, Lee SD (2007) Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 58(4):544\u2013550","journal-title":"Psychiatr Serv"},{"key":"1807_CR64","volume":"1","author":"G Faulkner","year":"2007","unstructured":"Faulkner G, Cohn T, Remington G (2007) Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 1, CD005148","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1807_CR65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","volume":"22","author":"T Baptista","year":"2008","unstructured":"Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477\u2013495","journal-title":"CNS Drugs"},{"issue":"7","key":"1807_CR66","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/npp.2010.21","volume":"35","author":"L Maayan","year":"2010","unstructured":"Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35(7):1520\u20131530","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1807_CR67","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","volume":"71","author":"RM Procyshyn","year":"2010","unstructured":"Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566\u2013573","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1807_CR68","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1037\/a0031228","volume":"21","author":"HN Boyda","year":"2013","unstructured":"Boyda HN, Procyshyn RM, Tse L, Xu J, Jin CH, Wong D, Pang CC, Honer WG, Barr AM (2013) Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 21(2):164\u2013171","journal-title":"Exp Clin Psychopharmacol"},{"key":"1807_CR69","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.10.006","volume":"48","author":"HN Boyda","year":"2014","unstructured":"Boyda HN, Procyshyn RM, Asiri Y, Wu C, Wang CK, Lo R, Pang CC, Honer WG, Barr AM (2014) Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 48:170\u2013176","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"1807_CR70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","volume":"37","author":"HN Boyda","year":"2012","unstructured":"Boyda HN, Procyshyn RM, Tse L, Hawkes E, Jin CH, Pang CC, Honer WG, Barr AM (2012) Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 37(6):407\u2013415","journal-title":"J Psychiatry Neurosci"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1807-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1807-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T20:39:41Z","timestamp":1747514381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1807-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,28]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1807-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,28]]}}}